Eletriptan use while Breastfeeding
Medically reviewed by Drugs.com. Last updated on Nov 15, 2022.
Drugs containing Eletriptan: Relpax
Eletriptan Levels and Effects while Breastfeeding
Summary of Use during Lactation
Limited information indicates that a maternal dose of eletriptan up to 80 mg daily produces low levels in milk and would not be expected to cause any adverse effects in breastfed infants.
Drug Levels
Eletriptan is metabolized to an active metabolite that has a longer half-life than eletriptan, but its serotonin agonist activity is only about 10% that of eletriptan.
Maternal Levels. Eight lactating women who were at least 1 month postpartum were given a single 80 mg oral dose of eletriptan. An average of 12.9 mcg was excreted in the 24 hours after the dose. At 24 hours, breastmilk levels averaged 1.7 mcg/L. The half-life in milk of eletriptan was 3.6 hours.[1] The active metabolite was not measured in breastmilk.
Three women who were at least 1 month postpartum used eletriptan to treat migraine provided one milk sample before the dose, then additional milk samples at 1, 2, 4, 8, 12 and 24 hours after the dose. Desmethyleletriptan was undetectable (< 1 nM) in milk. One mother took a 20 mg dose. The peak milk level of 18.2 mcg/L occurred at 2 hours after the dose. The average milk level was 5.7 mcg/L and the half-life in milk was 4 hours. Her infant’s daily dosage of eletriptan was 0.9 mcg/kg and the weight-adjusted infant dosage was 0.3% of the maternal dose. The two other women took a 40 mg dose. Peak milk levels of 78.1 and 102.4 mcg/L occurred at 2 hours after the dose and the half-lives in milk were 5.1 and 3.7 hours, respectively. The average milk levels were 24 and 23.5 mcg/L, respectively. Their infants’ daily dosages of eletriptan were 3.6 and 3.5 mcg/kg and their weight-adjusted infant dosages were 0.6% and 0.8% of the maternal dose. The overall average infant dosage was 0.6% of the maternal weight-adjusted dosage.[2]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
- 1.
-
Research FDA Center for Drug Evaluation and. NDA 21-016. Clinical pharmacology and biopharmaceutics reviews. 2002:8-9. Accessed 1/25/2020. https://www
.accessdata .fda.gov/drugsatfda_docs /nda/2002/21016_Relpax_BioPharmr .pdf. - 2.
-
Amundsen S, Nordeng H, Fuskevåg OM, et al. Transfer of triptans into human breast milk and estimation of infant drug exposure through breastfeeding. Basic Clin Pharmacol Toxicol. 2021;128:795–804. [PubMed: 33730376]
Substance Identification
Substance Name
Eletriptan
CAS Registry Number
177834-92-3
Drug Class
Breast Feeding
Lactation
Serotonin Receptor Agonists
Serotonin 5-HT1 Receptor Agonists
Triptans
Vasoconstrictor Agents
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
LactMed is a registered trademark of the U.S. Department of Health and Human Services.
- Drug Levels and Effects
- Substance Identification
More about eletriptan
- Check interactions
- Pricing & coupons
- Reviews (177)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Drug class: antimigraine agents
- En español
Patient resources
Other brands
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.